Join Now

BioMed Nexus Update: Feb 14 News & Tools

Table of Contents

Concord Biotech Plummets: Shares crashed 27% by Feb 14, capping a brutal week after a failed trial sank hopes—smallcap biotech’s reeling. Economic Times calls it a market overreaction; X debates if it’s a buying dip. Read more

Pharma M&A Heats Up: EY’s Feb 14 report highlighted a shift to smaller, smarter pharma deals—2025’s off to a cautious start. Big players like Pfizer are nibbling at agile biotechs—strategic or just safe? Read more

MedTech Wearable Tease: Fitbit unveiled a cardiac sensor Feb 14 with real-time AFib alerts—docs see potential, but privacy concerns linger. MedTech’s wearable race accelerates; will it stick? Read more


Quick Take: Feb 14’s biotech bust, pharma deals, and MedTech tease pull the sector in all directions—volatility reigns.

Featured Articles

FDA's 44-Day Approval, Sarepta CEO Exits, BioMarin Pulls Roctavian - BioMed Nexus Biotech Newsletter
Daily Updates

FDA’s 44-Day Approval, Sarepta CEO Exits, BioMarin Pulls Roctavian

Boehringer Ingelheim’s zongertinib has secured a landmark 44-day FDA approval under the new National Priority Voucher pilot, fundamentally rewriting the timeline for bringing critical drugs to market. Meanwhile, the sudden retirement of Sarepta’s Doug Ingram marks a generational leadership shift in the embattled Duchenne muscular

Read More »
GSK's $950M PAH Bet, FDA Bespoke Pathway, MacroGenics Clinical Hold- BioMed Nexus Biotech Newsletter
Daily Updates

GSK’s $950M PAH Bet, FDA “Bespoke” Pathway, MacroGenics Clinical Hold

GSK has re-entered the pulmonary arterial hypertension arena with a $950 million acquisition of 35Pharma, positioning itself to directly challenge Merck’s blockbuster Winrevair with a Phase 2-ready activin ligand designed for superior bleeding and safety profiles. Meanwhile, the FDA’s landmark “Ultra-Rare Framework” codifies regulatory flexibility

Read More »

Join 85,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters